DK1583542T3 - Sammensætninger og fremgangsmåder til antiviral kombinationsterapi - Google Patents

Sammensætninger og fremgangsmåder til antiviral kombinationsterapi

Info

Publication number
DK1583542T3
DK1583542T3 DK04701819T DK04701819T DK1583542T3 DK 1583542 T3 DK1583542 T3 DK 1583542T3 DK 04701819 T DK04701819 T DK 04701819T DK 04701819 T DK04701819 T DK 04701819T DK 1583542 T3 DK1583542 T3 DK 1583542T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
combination therapy
antiviral combination
antiviral
Prior art date
Application number
DK04701819T
Other languages
Danish (da)
English (en)
Inventor
Terrence C Dahl
Mark M Menning
Reza Oliyai
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1583542(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DK1583542T3 publication Critical patent/DK1583542T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK04701819T 2003-01-14 2004-01-13 Sammensætninger og fremgangsmåder til antiviral kombinationsterapi DK1583542T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44030803P 2003-01-14 2003-01-14
US44024603P 2003-01-14 2003-01-14
PCT/US2004/000832 WO2004064845A1 (en) 2003-01-14 2004-01-13 Compositions and methods for combination antiviral therapy

Publications (1)

Publication Number Publication Date
DK1583542T3 true DK1583542T3 (da) 2008-09-22

Family

ID=32776014

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04701819T DK1583542T3 (da) 2003-01-14 2004-01-13 Sammensætninger og fremgangsmåder til antiviral kombinationsterapi

Country Status (26)

Country Link
US (11) US20040224917A1 (ja)
EP (4) EP1923063A3 (ja)
JP (8) JP2006515624A (ja)
KR (3) KR20090053867A (ja)
CN (2) CN102670629B (ja)
AP (1) AP2089A (ja)
AT (1) ATE398455T1 (ja)
AU (3) AU2004206821C1 (ja)
BR (1) BRPI0406760A (ja)
CA (2) CA2512475C (ja)
CY (1) CY1108355T1 (ja)
DE (1) DE602004014470D1 (ja)
DK (1) DK1583542T3 (ja)
EA (2) EA201100293A1 (ja)
ES (1) ES2308136T3 (ja)
HK (1) HK1079122A1 (ja)
HR (2) HRP20050619A2 (ja)
IL (1) IL169243A (ja)
IS (1) IS7977A (ja)
MX (1) MXPA05007016A (ja)
NO (3) NO337917B1 (ja)
NZ (1) NZ540728A (ja)
PL (2) PL378368A1 (ja)
PT (1) PT1583542E (ja)
SI (1) SI1583542T1 (ja)
WO (2) WO2004064846A1 (ja)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1923063A3 (en) * 2003-01-14 2009-04-08 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
ES2727577T3 (es) 2004-12-03 2019-10-17 Merck Sharp & Dohme Composición farmacéutica que contiene un agente antinucleante
EP1868628B1 (en) * 2005-04-08 2014-06-11 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
EP2842559A3 (en) * 2005-04-08 2015-03-18 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
EP2051703B1 (en) * 2005-12-14 2010-07-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
CN103275033B (zh) 2006-07-07 2015-04-29 吉里德科学公司 治疗剂的药代动力学特性调节剂
AU2007344507B2 (en) * 2007-01-20 2013-07-04 Merck Patent Gmbh Packaging containing soft capsules
WO2008096369A2 (en) * 2007-02-05 2008-08-14 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
US20100196273A1 (en) * 2007-02-12 2010-08-05 Board Of Regents, University Of Texas System Novel agent for in vivo pet imaging of tumor proliferation
US9891239B2 (en) 2007-02-23 2018-02-13 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CA2702055C (en) * 2007-10-10 2017-12-12 Mallinckrodt Baker, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
WO2009091586A2 (en) 2008-01-18 2009-07-23 North Carolina State University Peptides and methods of use as therapeutics and screening agents
WO2009094190A2 (en) 2008-01-25 2009-07-30 Chimerix, Inc. Methods of treating viral infections
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
SG173544A1 (en) 2009-02-06 2011-09-29 Gilead Sciences Inc Tablets for combination therapy
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
MX367937B (es) 2010-01-27 2019-09-12 Viiv Healthcare Co Combinaciones de compuestos que comprenden inhibidores de la integrasa de vih y otros agentes terapéuticos.
EP3216789A1 (en) 2010-02-12 2017-09-13 Chimerix, Inc. Methods of treating viral infection
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP2752422B1 (en) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselective synthesis of phosphorus containing actives
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
AU2011248620B2 (en) 2010-04-26 2015-11-26 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
EP2389929A1 (en) * 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of tenofovir
WO2011156594A2 (en) 2010-06-09 2011-12-15 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
AU2011288091B2 (en) * 2010-08-01 2016-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystals of Tenofovir disoproxil fumarate
PE20170521A1 (es) 2010-11-19 2017-05-27 Gilead Sciences Inc Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
US9550803B2 (en) 2011-05-06 2017-01-24 University Of Southern California Method to improve antiviral activity of nucleotide analogue drugs
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2794624B1 (en) 2011-12-22 2019-05-15 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
EA026138B1 (ru) 2012-02-03 2017-03-31 Джилид Сайэнс, Инк. Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций
CN103665043B (zh) * 2012-08-30 2017-11-10 江苏豪森药业集团有限公司 一种替诺福韦前药及其在医药上的应用
WO2014068265A1 (en) * 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9216996B2 (en) * 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
CN103127028A (zh) * 2013-03-14 2013-06-05 南京恒道医药科技有限公司 一种含有富马酸替诺福韦二吡呋酯的胶囊剂
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
NO2865735T3 (ja) 2013-07-12 2018-07-21
CA2918707A1 (en) * 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (ja) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
CN105399771B (zh) * 2014-07-21 2020-11-24 江苏豪森药业集团有限公司 替诺福韦前药晶型及其制备方法和用途
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
WO2016156124A1 (en) * 2015-03-27 2016-10-06 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising sembragiline
CN107531727B (zh) 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
US20170000807A1 (en) * 2015-06-30 2017-01-05 Gilead Sciences, Inc. Pharmaceutical formulations
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
SI3346995T1 (sl) * 2015-11-09 2019-11-29 Gilead Sciences Inc Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
US10450335B2 (en) 2015-12-15 2019-10-22 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
WO2018080903A1 (en) 2016-10-26 2018-05-03 Merck Sharp & Dohme Corp. Antiviral aryl-amide phosphodiamide compounds
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
EP3558322B1 (en) 2016-12-22 2021-09-29 Merck Sharp & Dohme Corp. Antiviral benzyl-amine phosphodiamide compounds
CN106749254B (zh) * 2017-01-10 2018-05-25 青岛科技大学 一种6-氨基嘌呤乙基萘乙酸酯类化合物及其作为植物生长调节剂的用途
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
GB201705087D0 (en) * 2017-03-30 2017-05-17 Univ Liverpool Method for producing a liquid composition
CN110769856A (zh) * 2017-04-18 2020-02-07 希普拉有限公司 用于治疗逆转录病毒感染的组合疗法
RU2662160C9 (ru) 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
KR102077060B1 (ko) * 2017-07-14 2020-02-13 주식회사 종근당 테노포비어 디소프록실 아스파르트산 염을 포함하는 약제학적 조성물
RU2666727C1 (ru) * 2017-07-18 2018-09-12 Андрей Александрович Иващенко Ингибитор вируса гепатита В (ВГВ)
TR201713954A2 (tr) 2017-09-20 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP3823629A4 (en) 2018-07-19 2022-05-04 Merck Sharp & Dohme Corp. PHOSPHINAMIDE PRODRUGS OF TENOFOVIR
RU2726210C2 (ru) * 2018-12-27 2020-07-09 Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" Комбинация противовирусных средств, набор и способ лечения на ее основе
CN110261631A (zh) * 2019-07-26 2019-09-20 重庆德方信息技术有限公司 用于健康检测装置的滴液机构
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN113880898B (zh) * 2020-10-30 2023-07-25 杭州拉林智能科技有限公司 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568164A (en) 1896-09-22 Motor attachment for bicycles
CH389608A (de) 1960-01-19 1965-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Äthern
US3524846A (en) * 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3622677A (en) 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
CH531000A (de) * 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4003878A (en) * 1972-12-07 1977-01-18 Avtex Fibers Inc. Method of preparing an alkali-metal salt of an alkoxysulfonated benzoic acid glycol ester
GB1523865A (en) 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4384005A (en) 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
GB2111043B (en) 1980-12-12 1985-02-06 Ciba Geigy Ag Novel cephalosporin esters
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
JPS5879983A (ja) * 1981-11-06 1983-05-13 Kanebo Ltd 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
US5155268A (en) * 1984-05-04 1992-10-13 The Upjohn Company Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
CS263951B1 (en) 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
NZ222553A (en) 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
WO1988005438A1 (en) 1987-01-20 1988-07-28 Sri International Antiviral agents
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA885709B (en) 1987-08-19 1989-04-26 Fujisawa Pharmaceutical Co Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer)
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5684164A (en) 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5453503A (en) 1988-10-11 1995-09-26 Eli Lilly And Company Azetidinone intermediates to carbacephalosporins and process
CA2001715C (en) 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
UA45942A (uk) 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5827727A (en) 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
AU653542B2 (en) 1990-07-19 1994-10-06 Beecham Group Plc Antiviral phosphono-alken derivatives of purines
AU653552B2 (en) * 1990-08-10 1994-10-06 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Novel process for the preparation of nucleotides
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
CA2054126A1 (en) 1990-10-26 1992-04-27 Michiyuki Sendai Cephem compounds, their production and use
US5587480A (en) 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5208221A (en) * 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
GB9026164D0 (en) 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
IL100965A (en) 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
SK279262B6 (sk) * 1991-05-16 1998-08-05 Glaxo Group Limited Protivírusová zmes, farmaceutický prostriedok s je
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) * 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
AU4356693A (en) 1992-06-23 1994-01-24 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US5432172A (en) 1992-08-03 1995-07-11 The Research Foundation Of State University Of New York Biological applications of alkaloids derived from the tunicate Eudistoma sp.
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CA2107644A1 (en) 1992-10-28 1994-04-29 David R. Magnin .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd
WO1994018215A1 (en) * 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
AU691527B2 (en) 1993-09-17 1998-05-21 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JPH09506333A (ja) 1993-09-17 1997-06-24 ギリアード サイエンシーズ，インコーポレイテッド 治療化合物の投薬方法
WO1995032957A1 (en) 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
US5514557A (en) 1994-06-06 1996-05-07 Genetic Testing Institute Inc. Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins
PE32296A1 (es) 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
US5512596A (en) * 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
US5486806A (en) * 1994-11-09 1996-01-23 Firari; Harold A. Anti-hijacking and theft prevention device for motor vehicles
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5618964A (en) * 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
WO1996040191A1 (en) * 1995-06-07 1996-12-19 Trimeris, Inc. The treatment of hiv and other viral infections using combinatory therapy
US5733788A (en) * 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
JP4033494B2 (ja) 1996-07-26 2008-01-16 ギリヤド サイエンシーズ， インコーポレイテッド ヌクレオチドアナログ
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
AU4428397A (en) * 1996-09-20 1998-04-14 Warner-Lambert Company Oral compositions containing a zinc compound
GB9622681D0 (en) 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
CN1763056B (zh) * 1997-07-25 2013-01-16 吉尔利德科学股份有限公司 核苷酸类似物组合物
US6270957B1 (en) * 1997-08-26 2001-08-07 Wisconsin Alumni Research Foundation Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
CO4970782A1 (es) 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (en) 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
AU4716299A (en) 1998-06-24 2000-01-10 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
CN1141305C (zh) 1998-08-12 2004-03-10 三角药物公司 生产1,3-氧硫戊环核苷的方法
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
DK1382343T3 (da) * 1998-11-02 2010-04-26 Gilead Sciences Inc Kombinationsterapi til behandling af hepatitis B-virus
GB9909154D0 (en) 1999-04-22 1999-06-16 Nippon Glaxo Limited Pharmaceutical formulation
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
AU2001240578A1 (en) 2000-02-02 2001-08-14 Axxima Pharmaceuticals Ag Pharmaceutically active aromatic guanylhydrazones
BRPI0108435B8 (pt) * 2000-02-29 2021-05-25 Bristol Myers Squibb Co formulação e uso de entecavir de baixa dose
CZ304734B6 (cs) * 2000-07-21 2014-09-10 Gilead Sciences, Inc. Způsob přípravy 9-[2-(fosfonomethoxy)propyl]adeninu a 9-[2-(fosfonomethoxy)ethyl]adeninu
CA2432287A1 (en) 2000-12-15 2002-09-06 Triangle Pharmaceuticals, Inc. Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor
US6900315B2 (en) 2001-02-06 2005-05-31 Yale University 2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms
EP1903041B1 (en) 2001-03-01 2015-02-18 AbbVie Inc. Polymorphic and other crystalline forms of cis-FTC
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003045327A2 (en) 2001-11-27 2003-06-05 Bristol-Myers Squibb Company Efavirenz tablet formulation having unique biopharmaceutical characteristics
EP1854454B1 (en) 2002-01-16 2013-11-06 Boehringer Ingelheim Pharma GmbH & Co. KG Method for the preparation of amorphous telmisartan
CA2474056A1 (en) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
CA2481449A1 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
CN100406017C (zh) 2002-12-09 2008-07-30 佐治亚大学研究基金会 用于对抗hiv抗性株的二氧戊环基胸腺嘧啶及其组合物
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
EP1923063A3 (en) 2003-01-14 2009-04-08 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
EP1631263B1 (fr) * 2003-06-06 2014-02-26 Ethypharm Comprime orodispersible multicouche
CA2598607A1 (en) 2005-01-18 2006-07-27 Adra N. Chaker Methods and compositions for cell-cycle regulation
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
EP1899332A1 (en) 2005-06-24 2008-03-19 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
ES2438019T3 (es) * 2005-07-22 2014-01-15 Cytodyn, Inc. Procedimientos para reducir la carga viral en pacientes infectados por el VIH-1
US7448494B2 (en) * 2005-08-10 2008-11-11 Certain Teed Corporation Loose fill insulation packaged with additive
EP2051703B1 (en) 2005-12-14 2010-07-21 Cipla Limited Pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit
GB0525898D0 (en) 2005-12-20 2006-02-01 Pharmo Bioscience As Screening compounds for activity in modulating chloride ion transport
JP2010515771A (ja) 2007-01-16 2010-05-13 プロテオロジクス リミテッド トポイソメラーゼインヒビターの治療効果を増強する方法
EP2361247A4 (en) 2008-08-06 2012-08-08 Bionevia Pharmaceuticals Inc FLUPIRTINHYDROCHLORID-maleic acid co-crystal
WO2012003413A1 (en) 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
PE20170521A1 (es) 2010-11-19 2017-05-27 Gilead Sciences Inc Combinacion farmaceutica que comprende rilpivirina hcl, tenofovir disoproxil fumarato y emtricitabina

Also Published As

Publication number Publication date
US8592397B2 (en) 2013-11-26
WO2004064845A8 (en) 2004-09-23
US20090036408A1 (en) 2009-02-05
US8716264B2 (en) 2014-05-06
NO20150656A1 (no) 2005-10-13
CN105596356A (zh) 2016-05-25
US20090143314A1 (en) 2009-06-04
KR100860136B1 (ko) 2008-09-25
KR20090053867A (ko) 2009-05-27
NO20053817L (no) 2005-10-13
IL169243A (en) 2008-12-29
DE602004014470D1 (de) 2008-07-31
EP3025718A1 (en) 2016-06-01
EP1923063A3 (en) 2009-04-08
CA2512475C (en) 2009-06-02
PL408254A1 (pl) 2014-07-21
EP1585527A1 (en) 2005-10-19
US20150111855A1 (en) 2015-04-23
US20170273994A1 (en) 2017-09-28
EP1923063A2 (en) 2008-05-21
AU2009200414A1 (en) 2009-02-26
AP2089A (en) 2010-01-11
JP2014037430A (ja) 2014-02-27
AU2004206821A1 (en) 2004-08-05
NO337917B1 (no) 2016-07-11
AU2004206821B2 (en) 2009-02-26
ES2308136T3 (es) 2008-12-01
AU2009200414B2 (en) 2011-12-08
WO2004064845A1 (en) 2004-08-05
PT1583542E (pt) 2008-09-17
AU2004206827A1 (en) 2004-08-05
EA201100293A1 (ru) 2011-08-30
PL378368A1 (pl) 2006-04-03
JP2015098488A (ja) 2015-05-28
US9457036B2 (en) 2016-10-04
US20060246130A1 (en) 2006-11-02
EA015145B1 (ru) 2011-06-30
JP2010120957A (ja) 2010-06-03
NO20053817D0 (no) 2005-08-12
EP1583542B1 (en) 2008-06-18
CA2512475A1 (en) 2004-08-05
NO20171193A1 (no) 2005-10-13
HRP20050619A2 (en) 2005-10-31
US20140213556A1 (en) 2014-07-31
JP2019052174A (ja) 2019-04-04
EP1583542A1 (en) 2005-10-12
NZ540728A (en) 2008-08-29
US9744181B2 (en) 2017-08-29
US20170232019A1 (en) 2017-08-17
US20040224916A1 (en) 2004-11-11
MXPA05007016A (es) 2005-09-12
KR20080032014A (ko) 2008-04-11
CN102670629B (zh) 2016-02-24
IS7977A (is) 2005-08-12
HK1079122A1 (en) 2006-03-31
JP4996241B2 (ja) 2012-08-08
NO340951B1 (no) 2017-07-24
CY1108355T1 (el) 2014-02-12
US20060234982A1 (en) 2006-10-19
EA200501134A1 (ru) 2005-12-29
EP1583542B9 (en) 2008-10-22
HRP20140379A2 (hr) 2014-07-18
JP2017057232A (ja) 2017-03-23
AP2005003348A0 (en) 2005-06-30
CA2512319A1 (en) 2004-08-05
AU2004206821C1 (en) 2009-10-01
BRPI0406760A (pt) 2005-12-20
US20150111856A1 (en) 2015-04-23
SI1583542T1 (sl) 2008-12-31
CN102670629A (zh) 2012-09-19
JP2021004264A (ja) 2021-01-14
WO2004064846A1 (en) 2004-08-05
US20040224917A1 (en) 2004-11-11
ATE398455T1 (de) 2008-07-15
KR20050092755A (ko) 2005-09-22
JP2006515624A (ja) 2006-06-01
JP2006516570A (ja) 2006-07-06

Similar Documents

Publication Publication Date Title
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
NO20055837D0 (no) Immunsupprimerende forbindelser og sammensetninger
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
DK1606283T3 (da) P38-inhibitorer og fremgangsmåder til anvendelse deraf
IS8037A (is) P38-hindrar og aðferðir til notkunar þeirra
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK1592686T3 (da) Gyrase-inhibitorer og anvendelser deraf
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
ITFI20030104A1 (it) Apparecchiatura per terapie di ipertemia non distruttiva
GB0203933D0 (en) Portable dummy sterilizer
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DK1590321T3 (da) Arylalkylcarbamat-derivater, fremstilling og terapeutisk anvendelse deraf
NO20050689L (no) Terapeutisk anvendelse
IS8489A (is) Umritunarstillar og aðferðir þeirra
DK1882054T3 (da) Korrosionsbeskyttelsesanordning og fremgangsmåde
DK1597171T3 (da) Terapeutisk mikroskum
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf
NO20055582D0 (no) Preparater og fremgangsmater omfattende gastrinforbindelser
DK1572950T3 (da) Enkeltdomæne TDF-relaterede forbindelser og analoger deraf
IS7961A (is) Díarýlmetýlídenpíperidínafleiður, lyfjablöndur þeirra og notkun þeirra
SE0300181L (sv) Simuleringsförfarande
NO20044064L (no) Fremgangmater og sammensetninger for gastrointestinal-toksisitet indusert av cytoablativ terapi
GB0327050D0 (en) Therapeutic methods compositions and uses